David Nierengarten
Stock Analyst at Wedbush
(3.54)
# 841
Out of 4,851 analysts
211
Total ratings
41.86%
Success rate
6.56%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Downgrades: Neutral | $128 → $129 | $128.10 | +0.70% | 5 | Jun 2, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Neutral | $10 → $12 | $10.20 | +17.65% | 3 | May 28, 2025 | |
| NTLA Intellia Therapeutics | Reiterates: Neutral | $10 | $7.67 | +30.38% | 9 | May 19, 2025 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $5 | $2.45 | +104.08% | 8 | May 16, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $29 → $27 | $16.72 | +61.48% | 8 | Apr 16, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Reiterates: Outperform | $34 | $28.88 | +17.73% | 3 | Apr 16, 2025 | |
| ARGX argenx SE | Reiterates: Outperform | $715 | $574.30 | +24.50% | 19 | Apr 16, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $3.13 | +251.44% | 3 | Mar 27, 2025 | |
| IMNM Immunome | Reiterates: Outperform | $33 | $9.02 | +265.85% | 6 | Mar 20, 2025 | |
| STRO Sutro Biopharma | Downgrades: Neutral | $8 → $2 | $0.91 | +119.93% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.42 | +252.11% | 15 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $11.16 | +177.78% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $46.72 | +64.81% | 6 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $21.27 | +88.06% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $36.50 | +146.58% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $30.82 | +52.50% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $3.98 | +276.88% | 6 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $99 → $115 | $76.79 | +49.77% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $4.96 | +363.71% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $9.08 | +120.26% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $11.68 | +242.47% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $16.59 | +171.25% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.78 | +461.80% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $1.97 | +813.71% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $47.32 | +20.46% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.39 | +1,190.66% | 8 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.34 | +49.25% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $5.64 | +77.30% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $0.23 | +4,709.79% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $36 | $9.10 | +295.60% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $1.32 | +809.09% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $17.15 | +232.36% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $7 | $0.37 | +1,797.02% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $3.02 | +16,456.29% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $4.34 | +1,282.49% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $7.69 | +147.07% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $36.57 | +105.09% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.18 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.32 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.88 | - | 3 | Nov 20, 2017 |
Blueprint Medicines
Jun 2, 2025
Downgrades: Neutral
Price Target: $128 → $129
Current: $128.10
Upside: +0.70%
iTeos Therapeutics
May 28, 2025
Downgrades: Neutral
Price Target: $10 → $12
Current: $10.20
Upside: +17.65%
Intellia Therapeutics
May 19, 2025
Reiterates: Neutral
Price Target: $10
Current: $7.67
Upside: +30.38%
Nuvation Bio
May 16, 2025
Reiterates: Outperform
Price Target: $5
Current: $2.45
Upside: +104.08%
NovoCure
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $16.72
Upside: +61.48%
Kiniksa Pharmaceuticals International,
Apr 16, 2025
Reiterates: Outperform
Price Target: $34
Current: $28.88
Upside: +17.73%
argenx SE
Apr 16, 2025
Reiterates: Outperform
Price Target: $715
Current: $574.30
Upside: +24.50%
Perspective Therapeutics
Mar 27, 2025
Reiterates: Outperform
Price Target: $11
Current: $3.13
Upside: +251.44%
Immunome
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $9.02
Upside: +265.85%
Sutro Biopharma
Mar 14, 2025
Downgrades: Neutral
Price Target: $8 → $2
Current: $0.91
Upside: +119.93%
Mar 6, 2025
Reiterates: Neutral
Price Target: $5
Current: $1.42
Upside: +252.11%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $11.16
Upside: +177.78%
Feb 12, 2025
Reiterates: Outperform
Price Target: $77
Current: $46.72
Upside: +64.81%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $21.27
Upside: +88.06%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $36.50
Upside: +146.58%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $30.82
Upside: +52.50%
Sep 30, 2024
Reiterates: Outperform
Price Target: $15
Current: $3.98
Upside: +276.88%
Sep 16, 2024
Maintains: Outperform
Price Target: $99 → $115
Current: $76.79
Upside: +49.77%
Sep 10, 2024
Reiterates: Outperform
Price Target: $23
Current: $4.96
Upside: +363.71%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $9.08
Upside: +120.26%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $11.68
Upside: +242.47%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $16.59
Upside: +171.25%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.78
Upside: +461.80%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $1.97
Upside: +813.71%
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $47.32
Upside: +20.46%
Aug 8, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.39
Upside: +1,190.66%
May 29, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.34
Upside: +49.25%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $5.64
Upside: +77.30%
May 10, 2024
Reiterates: Outperform
Price Target: $11
Current: $0.23
Upside: +4,709.79%
May 10, 2024
Maintains: Outperform
Price Target: $34 → $36
Current: $9.10
Upside: +295.60%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $1.32
Upside: +809.09%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $17.15
Upside: +232.36%
Feb 29, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $0.37
Upside: +1,797.02%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $3.02
Upside: +16,456.29%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $4.34
Upside: +1,282.49%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $7.69
Upside: +147.07%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $36.57
Upside: +105.09%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.18
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.32
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $4.88
Upside: -